Avicanna Announces Receipt of Management Cease Trade Order and Provides Bi-Weekly Status Update

Provided By GlobeNewswire

Last update: Apr 7, 2025

Auditor Licensing & Personnel Issues Delays Issuance of Audit Opinion
The Company expects to file within 1 week

TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, that further to its March 31, 2025 new release, its application for a management cease trade order (“MCTO”) under National Policy 12-203 – Management Cease ‎Trade Orders (“NP 12-203“) has been approved by the Ontario Securities Commission (“OSC”). The MCTO does ‎not affect the ability of investors who are not insiders to trade in the securities of the Company.‎